Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Kareem Abdul-Jabbar, one of the greatest basketball players of all time, known for his unblockable signature "sky hook" shot, has announced that he was diagnosed late last year with a rare type...
-- Fanapt (iloperidone), an antipsychotic therapy, is indicated in US for the acute treatment of schizophrenia in adults, set for US launch in early 2010 -- Addition of Fanapt will strengthen...
PRINCETON, N.J., July 24 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com/), an online investment newsletter focused on long-term growth and income-generating stocks, has provided...
DALLAS, Dec. 17 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting:...
VANCOUVER, April 25 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported financial results for the first quarter ended March 31, 2008. Unless specified otherwise, all...
Facility on Track to be the First to Manufacture New Cell Cultured-Derived Influenza Vaccines in the US; New Plant Will Create More than 350 New Jobs Novartis has broken ground on construction...
In the news release, Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure, issued earlier today by Novartis...
FRIMLEY, England, September 21 /PRNewswire-FirstCall/ -- - Exjade(R), a Breakthrough Once-Daily Oral Iron Chelator, Now Available in the UK Novartis today announced the UK approval of Exjade(R...
Popular blood pressure medication is now approved to treat patients after a heart attack. EAST HANOVER, N.J., Aug. 3 /PRNewswire-FirstCall/ -- FORMAT: VNR, nat sound pass, loose b-roll...
Novartis Delivers Strong Double-Digit Growth and Margin Expansion in First Nine Months BASEL, Switzerland, October 21 /PRNewswire-FirstCall/ -- Key figures First nine months Nine months...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
